Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Ruxolitinib in Pyoderma Gangrenosum
NCT07783412Phase 2Recruiting
- Sponsor
- Oregon Health & Science University
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib cream in pyoderma gangrenosum (PG), sponsored by Oregon Health & Science University. Started Sep 2026; status: recruiting.
02
Drugs
ruxolitinib cream
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT07783412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783412.